Suppr超能文献

非侵入性胚胎活力检测与常规体外受精对体外受精/卵胞浆内单精子注射患者活产率的影响:一项双盲、多中心、随机对照试验的研究方案。

Effect of noninvasive embryo viability testing versus conventional IVF on the live birth rate in IVF/ICSI patients: a study protocol for a double-blind, multicenter, randomized controlled trial.

机构信息

Shenzhen Key Laboratory of Fertility Regulation, Reproductive Medicine Center, The University of Hong Kong-Shenzhen Hospital, No. 1 Haiyuan Road, Shenzhen, 518053, Guangdong, China.

Department of Obstetrics and Gynecology, Chinese PLA General Hospital, Beijing, 100853, China.

出版信息

BMC Pregnancy Childbirth. 2023 Sep 6;23(1):641. doi: 10.1186/s12884-023-05892-z.

Abstract

BACKGROUND

Preimplantation genetic testing for aneuploidy (PGT-A) was demonstrated to be superior to conventional IVF in reducing the incidence of miscarriage and abnormal offspring after the first embryo transfer (ET). PGT-A requires several embryo trophectoderm cells, but its negative impacts on embryo development and long-term influence on the health conditions of conceived children have always been a concern. As an alternative, noninvasive PGT-A (niPGT-A) approaches using spent blastocyst culture medium (SBCM) achieved comparable accuracy with PGT-A in several pilot studies. The main objective of this study is to determine whether noninvasive embryo viability testing (niEVT) results in better clinical outcomes than conventional IVF after the first embryo transfer. Furthermore, we further investigated whether niEVT results in higher the live birth rate between women with advanced maternal age (AMA, > 35 years old) and young women or among patients for whom different fertilization protocols are adopted.

METHODS

This study will be a double-blind, multicenter, randomized controlled trial (RCT) studying patients of different ages (20-43 years) undergoing different fertilization protocols (in vitro fertilization [IVF] or intracytoplasmic sperm injection [ICSI]). We will enroll 1140 patients at eight reproductive medical centers over 24 months. Eligible patients should have at least two good-quality blastocysts (better than grade 4 CB). The primary outcome will be the live birth rate of the first embryo transfer (ET). Secondary outcomes will include the clinical pregnancy rate, ongoing pregnancy rate, miscarriage rate, cumulative live birth rate, ectopic pregnancy rate, and time to pregnancy.

DISCUSSION

In this study, patients who undergo noninvasive embryo viability testing (niEVT) will be compared to women treated by conventional IVF. We will determine the effects on the pregnancy rate, miscarriage rate, and live birth rate and adverse events. We will also investigate whether there is any difference in clinical outcomes among patients with different ages and fertilization protocols (IVF/ICSI). This trial will provide clinical evidence of the effect of noninvasive embryo viability testing on the clinical outcomes of the first embryo transfer.

TRIAL REGISTRATION

Chinese Clinical Trial Registry (ChiCTR) Identifier: ChiCTR2100051408. 9 September 2021.

摘要

背景

着床前胚胎遗传学检测(PGT-A)已被证明可降低首次胚胎移植(ET)后流产和异常后代的发生率,优于传统的体外受精(IVF)。PGT-A 需要几个胚胎滋养外胚层细胞,但它对胚胎发育的负面影响以及对受孕儿童健康状况的长期影响一直是人们关注的问题。作为替代方案,使用废弃的囊胚培养液(SBCM)的非侵入性 PGT-A(niPGT-A)方法在几项试点研究中取得了与 PGT-A 相当的准确性。本研究的主要目的是确定非侵入性胚胎活力检测(niEVT)在首次胚胎移植后是否比传统的 IVF 带来更好的临床结局。此外,我们还进一步研究了 niEVT 是否会在高龄产妇(>35 岁)和年轻女性之间,或者在采用不同受精方案的患者之间提高活产率。

方法

这是一项双盲、多中心、随机对照试验(RCT),研究不同年龄(20-43 岁)和不同受精方案(体外受精[IVF]或胞浆内精子注射[ICSI])的患者。我们将在 24 个月内从 8 个生殖医学中心招募 1140 名患者。符合条件的患者应至少有 2 个优质囊胚(优于 4CB 级)。主要结局是首次胚胎移植(ET)的活产率。次要结局包括临床妊娠率、持续妊娠率、流产率、累积活产率、宫外孕率和妊娠时间。

讨论

在本研究中,将比较接受非侵入性胚胎活力检测(niEVT)的患者与接受常规 IVF 治疗的女性。我们将确定对妊娠率、流产率和活产率以及不良事件的影响。我们还将研究不同年龄和受精方案(IVF/ICSI)的患者之间的临床结局是否存在差异。该试验将为非侵入性胚胎活力检测对首次胚胎移植临床结局的影响提供临床证据。

试验注册

中国临床试验注册中心(ChiCTR)标识符:ChiCTR2100051408。2021 年 9 月 9 日。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e70/10483849/dbaaedbcc524/12884_2023_5892_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验